ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Biologics

Fujifilm to invest almost $1 billion in Danish biologics plant

by Michael McCoy
June 20, 2020 | APPEARED IN VOLUME 98, ISSUE 24

Fujifilm will spend about $930 million to expand the biologic drug facility in Hillerød, Denmark, that it acquired last year from Biogen. The Japanese firm says the project will double the plant’s active pharmaceutical ingredient capacity, making it one of the few large-scale biologic operations in the contract manufacturing business. Potential customers for the new capacity include the COVID-19 Therapeutics Accelerator, an initiative launched by the Bill & Melinda Gates Foundation, Wellcome, and Mastercard. The accelerator recently reserved future production capacity at the plant.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment